The $1.5 billion acquisition of BioLife Solutions accelerates leadership in cell therapy, adds a highly complementary portfolio, and is expected to be accretive to growth, margins, and EPS from year one. Integration is planned over 12–24 months, with at least $20 million in year one synergies and significant cross-selling opportunities, especially in Asia.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.